These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11353611)

  • 1. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.
    Dupuis A; Couet W; Paquereau J; Debarre S; Portron A; Jamois C; Bouquet S
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1682-7. PubMed ID: 11353611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia.
    Limosin A; Dupuis A; Lamarche I; Mimoz O; Paquereau J; Couet W
    J Antimicrob Chemother; 2004 Jul; 54(1):187-92. PubMed ID: 15163649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of imipenem in rats with acute renal failure.
    Dupuis A; Limosin A; Paquereau J; Mimoz O; Couet W; Bouquet S
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3607-9. PubMed ID: 11709350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats.
    Chenel M; Barbot A; Dupuis A; Mimoz O; Paquereau J; Bouquet S; Couet W
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1952-7. PubMed ID: 12760873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convulsant activity and pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats.
    Roy B; Bose A; Bhaumik U; Das A; Chatterjee N; Ghosh A; Darbar S; Sarkar AK; Sengupta P; Pal TK
    J Pharm Sci; 2010 Mar; 99(3):1535-47. PubMed ID: 19670296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses.
    Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R
    J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
    Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats.
    Chenel M; Marchand S; Dupuis A; Lamarche I; Paquereau J; Pariat C; Couet W
    Br J Pharmacol; 2004 May; 142(2):323-30. PubMed ID: 15155539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue distribution of imipenem in critically ill patients.
    Tegeder I; Schmidtko A; Bräutigam L; Kirschbaum A; Geisslinger G; Lötsch J
    Clin Pharmacol Ther; 2002 May; 71(5):325-33. PubMed ID: 12011818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
    Cox EH; Kuipers JA; Danhof M
    Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat.
    Mandema JW; Wada DR
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1185-94. PubMed ID: 8531080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats.
    Trocóniz IF; Garrido MJ; García E; Suárez E; Calvo R
    J Pharm Sci; 1997 Feb; 86(2):252-6. PubMed ID: 9040105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
    Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ
    Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat.
    Bol CJJG ; Danhof M; Stanski DR; Mandema JW
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1051-8. PubMed ID: 9399976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG.
    Groenendaal D; Freijer J; de Mik D; Bouw MR; Danhof M; de Lange EC
    Br J Pharmacol; 2007 Jul; 151(5):713-20. PubMed ID: 17471181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous regional infusion of imipenem for antimicrobial chemoprophylaxis in orthopaedic surgery.
    Vrettou I; Voyagis GS
    Eur J Anaesthesiol; 1998 Nov; 15(6):801-2. PubMed ID: 9884874
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.